Aktienanalyse zu Theravance Biopharma Inc (TBPH)TBPHTheravance Biopharma Inc

Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development and commercialization of medicines for the specialty respiratory and neurologic diseases. The Company operates through a single segment, namely, development and commercialization of human therapeutics. Its product, YUPELRI (revefenacin) inhalation solution, is a nebulized long-acting muscarinic antagonist used for the treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in the lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Its Ampreloxetine, is a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Theravance Biopharma is currently a hold. The stock is trading at $17.02, which is very close to the acquisition price of $17.00 per share set by Zymeworks. The recent downgrade from Jones Trading reflects caution regarding the company's future performance, particularly after the acquisition announcement. Additionally, the RSI is at 41.36, indicating that the stock is neither overbought nor oversold, suggesting a neutral position. The main risk is the uncertainty surrounding the acquisition and the company's future earnings potential, especially after the CYPRESS trial did not meet its primary endpoint, which could impact future revenue streams.

7 analysts cover TBPH: 4 rate it Buy, 0 Hold and 3 Sell. The average price target is 28.40.